10/10/2025 – AB Science today reports its revenues for the first half of 2025 and provides an update on its activities Download PDF Post navigationPreviousPrevious post:AB Science announces a slight delay in the publication of its 2025 half-year financial reportNextNext post:AB Science will hold a virtual conference on Thursday, October 16, 2025 from 2pm to 3pm CET to provide an update on the Phase 1 study with AB8939Related PostsAB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of functionDecember 11, 2025AB Science announces the successful completion of a 2.8 million euros private placementOctober 17, 2025Summary of the virtual conference held on October 16, 2025October 16, 2025AB Science webcast of October 16, 2025October 16, 2025AB Science will hold a virtual conference on Thursday, October 16, 2025 from 2pm to 3pm CET to provide an update on the Phase 1 study with AB8939October 14, 2025AB Science announces a slight delay in the publication of its 2025 half-year financial reportSeptember 30, 2025
AB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of functionDecember 11, 2025
AB Science announces the successful completion of a 2.8 million euros private placementOctober 17, 2025
AB Science will hold a virtual conference on Thursday, October 16, 2025 from 2pm to 3pm CET to provide an update on the Phase 1 study with AB8939October 14, 2025
AB Science announces a slight delay in the publication of its 2025 half-year financial reportSeptember 30, 2025
